A Combined QM/MM Approach to Protein−Ligand Interactions:  Polarization Effects of the HIV-1 Protease on Selected High Affinity Inhibitors

Journal of Medicinal Chemistry
2004.0

Abstract

HIV-1 protease inhibitors are one of the two widely used therapeutic agents for the treatment of HIV-infected patients. The investigation of HIV-1 protease-inhibitor interactions can provide further insight for developing new compounds that are still required due to the growing problem of drug resistance. To this end, a combined QM/MM approach was used to determine electrostatic and polarization interactions on three high affinity inhibitors, nelfinavir, mozenavir, and tipranavir. The present computational results show that explicit treatment of the polarization effect is particularly important since it can contribute as much as one-third of the total electrostatic interaction energy. Further, an amino acid decomposition analysis was applied to determine contributions of individual residues to the enzyme--inhibitor interactions. It was found that the 4-hydroxy-dihydropyrone substructure of tipranavir is especially suited for extended charge delocalization by interacting with the catalytic aspartates and isoleucines of the HIV-1 protease. The calculated electron density difference maps reaffirm and provide a means of visualizing these results.

Knowledge Graph

Similar Paper

A Combined QM/MM Approach to Protein−Ligand Interactions:  Polarization Effects of the HIV-1 Protease on Selected High Affinity Inhibitors
Journal of Medicinal Chemistry 2004.0
Is Quantum Mechanics Necessary for Predicting Binding Free Energy?
Journal of Medicinal Chemistry 2008.0
Experimental and ‘in silico’ analysis of the effect of pH on HIV-1 protease inhibitor affinity: Implications for the charge state of the protein ionogenic groups
Bioorganic & Medicinal Chemistry 2012.0
Three-Dimensional Quantitative Structure−Activity Relationship Study on Cyclic Urea Derivatives as HIV-1 Protease Inhibitors:  Application of Comparative Molecular Field Analysis
Journal of Medicinal Chemistry 1999.0
All-Atom Models for the Non-Nucleoside Binding Site of HIV-1 Reverse Transcriptase Complexed with Inhibitors:  A 3D QSAR Approach
Journal of Medicinal Chemistry 1996.0
Design of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1′-Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies
Journal of Medicinal Chemistry 2009.0
Design, Synthesis, and Biological Evaluation of Monopyrrolinone-Based HIV-1 Protease Inhibitors
Journal of Medicinal Chemistry 2003.0
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands
Bioorganic & Medicinal Chemistry Letters 2011.0
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl design
Journal of Medicinal Chemistry 1992.0
Modeling of Poly(ADP-ribose)polymerase (PARP) Inhibitors. Docking of Ligands and Quantitative Structure−Activity Relationship Analysis
Journal of Medicinal Chemistry 2001.0